BrainStorm (BCLI) Cell Therapeutics announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through June 30 to regain compliance with certain continued listing standards of The Nasdaq Capital Market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.